The challenge
Enlipsium had built a radiotherapy device with real clinical promise — and no way into Europe. As a non-EU company, it faced the structural reality that European institutional support, funding, and clinical access favour entities established in the EU, and that the doors that matter don't open to an unknown foreign applicant submitting cold. The technology was ready. The route was not.
The risk was the common one for non-EU medtech: spend a year and significant capital pushing on the wrong doors in the wrong order, arrive at funding bodies and clinical partners without context, and stall. What the company needed was not a list of programmes — it was a sequenced path through the institutions, with the relationships in place so each application arrived understood.
The approach
Innovation Park facilitated the entry as a deliberate sequence rather than a scattershot push. Each step established the credibility the next one required, so that by the time Enlipsium reached a funding application or a clinical conversation, it was the formalisation of a relationship that already existed — not a cold introduction.
Flanders Investment & Trade established the company's seriousness about Flanders; VLAIO opened the innovation-support pathway; imec and the KU Leuven tech-transfer office gave the technology institutional validation; and that credibility carried into clinical deployment relationships at UZ Leuven. Direct working access to each institution — namely VLAIO, FIT, imec, and EIT Health, among others — is what made the sequence move at pace.
The result
In twelve months, Innovation Park helped Enlipsium establish 13 institutional relationships, facilitated a €500K grant, and built a $50M+ qualified pipeline, with three contracts in active negotiation and a clinical deployment pathway into EU cancer centres. A company that began the year outside Europe with no foothold ended it inside the institutional ecosystem, funded, and on a path to deployment.
